MX2020005341A - Azaciclos sustituidos como moduladores alostericos positivos del receptor m1 muscarinico. - Google Patents

Azaciclos sustituidos como moduladores alostericos positivos del receptor m1 muscarinico.

Info

Publication number
MX2020005341A
MX2020005341A MX2020005341A MX2020005341A MX2020005341A MX 2020005341 A MX2020005341 A MX 2020005341A MX 2020005341 A MX2020005341 A MX 2020005341A MX 2020005341 A MX2020005341 A MX 2020005341A MX 2020005341 A MX2020005341 A MX 2020005341A
Authority
MX
Mexico
Prior art keywords
muscarinic
receptor
positive allosteric
allosteric modulators
azacycles
Prior art date
Application number
MX2020005341A
Other languages
English (en)
Inventor
Ramakrishna Nirogi
Anil Karbhari Shinde
Abdul Rasheed Mohammed
Rajesh Kumar Badange
Venkateswarlu Jasti
Raghava Choudary Palacharla
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of MX2020005341A publication Critical patent/MX2020005341A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención está relacionada a compuestos de formula (I), o sus formas isotópicas, estereoisomeros, tautomeros o sales farmacéuticamente aceptables como moduladores alostericos positivos del receptor M1 muscarinico (PAMs M1); la presente invención describe los métodos de preparación, composición farmacéutica, combinaciones y el uso de la fórmula del compuesto (I), sus estereoisomeros, formas isotópicas o sales farmacéuticamente aceptables de los mismos.
MX2020005341A 2017-11-23 2018-11-21 Azaciclos sustituidos como moduladores alostericos positivos del receptor m1 muscarinico. MX2020005341A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201741042082 2017-11-23
PCT/IB2018/059164 WO2019102365A1 (en) 2017-11-23 2018-11-21 Substituted azacycles as muscarinic m1 receptor positive allosteric modulators

Publications (1)

Publication Number Publication Date
MX2020005341A true MX2020005341A (es) 2020-08-13

Family

ID=64744766

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005341A MX2020005341A (es) 2017-11-23 2018-11-21 Azaciclos sustituidos como moduladores alostericos positivos del receptor m1 muscarinico.

Country Status (19)

Country Link
US (1) US12156871B2 (es)
EP (1) EP3713940B1 (es)
JP (1) JP7034284B2 (es)
KR (1) KR102443402B1 (es)
CN (1) CN111386270B (es)
AU (1) AU2018372664B2 (es)
BR (1) BR112020010138A2 (es)
CA (1) CA3082724C (es)
DK (1) DK3713940T3 (es)
EA (1) EA039902B1 (es)
HR (1) HRP20220736T1 (es)
HU (1) HUE058954T2 (es)
IL (1) IL274708B (es)
MA (1) MA50806A (es)
MX (1) MX2020005341A (es)
NZ (1) NZ764561A (es)
SG (1) SG11202004580WA (es)
WO (1) WO2019102365A1 (es)
ZA (1) ZA202002938B (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2588104B1 (en) * 2010-07-01 2014-12-10 Merck Sharp & Dohme Corp. Isoindolone m1 receptor positive allosteric modulators
EP2709451B1 (en) * 2011-05-17 2015-12-30 Merck Sharp & Dohme Corp. N-linked lactam m1 receptor positive allosteric modulators
US9586964B2 (en) 2011-10-28 2017-03-07 Vanderbilt University Substituted 2-(4-heterocyclylbenzyl)isoindolin-1-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M1
ES2811088T3 (es) 2014-04-23 2021-03-10 Takeda Pharmaceuticals Co Derivados de isoindolin-1-ona como actividad del modulador alostérico positivo del receptor M1 muscarínico colinérgico para el tratamiento de la enfermedad de Alzheimer
EP3394061B1 (en) * 2015-12-23 2020-03-11 Merck Sharp & Dohme Corp. 6,7-dihydro-5h-pyrrolo[3,4-b]pyridin-5-one allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2018005249A1 (en) * 2016-06-28 2018-01-04 Merck Sharp & Dohme Corp. Benzoisoquinolinone m1 receptor positive allosteric modulators

Also Published As

Publication number Publication date
EA202091302A1 (ru) 2020-08-17
US12156871B2 (en) 2024-12-03
JP2021504357A (ja) 2021-02-15
WO2019102365A1 (en) 2019-05-31
IL274708B (en) 2022-06-01
KR102443402B1 (ko) 2022-09-15
ZA202002938B (en) 2021-04-28
KR20200090854A (ko) 2020-07-29
DK3713940T3 (da) 2022-06-20
JP7034284B2 (ja) 2022-03-11
EA039902B1 (ru) 2022-03-25
EP3713940A1 (en) 2020-09-30
CN111386270B (zh) 2022-05-03
HUE058954T2 (hu) 2022-10-28
CN111386270A (zh) 2020-07-07
IL274708A (en) 2020-07-30
HRP20220736T1 (hr) 2022-09-02
CA3082724A1 (en) 2019-05-31
MA50806A (fr) 2020-09-30
CA3082724C (en) 2022-05-31
AU2018372664B2 (en) 2020-11-19
NZ764561A (en) 2021-12-24
SG11202004580WA (en) 2020-06-29
AU2018372664A1 (en) 2020-06-04
US20210369685A1 (en) 2021-12-02
EP3713940B1 (en) 2022-05-04
BR112020010138A2 (pt) 2020-11-10

Similar Documents

Publication Publication Date Title
MX2019002180A (es) Moduladores alostericos positivos del receptor m1 muscarinico.
CO2020013564A2 (es) Compuestos heteroaril tetracíclicos
PE20151437A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
SV2016005312A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cã�ncer
UY35663A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
PE20151438A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
CL2016002348A1 (es) Agonistas del receptor muscarínico
CL2018002335A1 (es) Moduladores alostéricos positivos del receptor de acetilcolina muscarínico m1
GT201600269A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
CO2022001814A2 (es) Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos
PE20151427A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
CR20170077A (es) Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
ECSP19062381A (es) Moduladores del receptor de estrógeno
CL2018002089A1 (es) Maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus procesos de preparación y su uso
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
MX2017000183A (es) Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides.
MX2018002738A (es) Derivados de piridin-2-ona fusionados triciclicos, y su uso como inhibidores de brd4.
BR112017009012A2 (pt) derivados de anel benzo de seis membros como inibidor de dpp-4 e seu uso
ECSP21071644A (es) Compuestos macrocíclicos como agonistas de sting
CL2020001817A1 (es) Moduladores del receptor c5a
CL2020001062A1 (es) Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos.
MX2017016619A (es) Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos.
CL2017002498A1 (es) Piridopirimidinonas y su uso como modulares del receptor nmda
MX2020004339A (es) Moduladores alostericos positivos del receptor m1 muscarinico.